- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Hematology | Clinical
Relapse Less Likely With Orca-T vs Standard Transplant in Hematologic Malignancies
October 01, 2022
In comparison with conventional transplant options, Orca-T may be more effective with a lower probability of infection in patients with hematologic malignancies.
Using Biology to Determine Type and Duration of Treatment in Waldenström Macroglobulinemia
September 30, 2022
Jorge J. Castillo, MD, will explore the challenges of managing WM. He will present on September 30, 2022, at 11:04 AM.
Multi-Stage Trial of Tagraxofusp Shows Frontline Efficacy in BPDCN
September 28, 2022
Andrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.
MDS Setting Looking to BCL2 Inhibitors for Improved Survival, Sequencing Options
September 28, 2022
Combinations of the BCL2 inhibitor venetoclax with hypomethylating agents are undergoing investigation to determine benefit in high-risk myelodysplastic syndrome.
Debating the Significance of MRD in Blood Cancers vs Initial Patient Characteristics
September 28, 2022
In the myeloma space, minimal residual disease negativity is prognostic of progression-free survival in relapsed or refractory patients. In leukemia, the biomarker combined with other prognostication techniques provides complex information that is clinically relevant.
Garcia-Manero Calls for New Combination Approaches in MDS
September 28, 2022
An overview of the single-cell level in early stage disease and describe new molecular classifications of myelodysplastic syndrome.
BPDCN: Epidemiology, Pathophysiology, and Diagnosis
September 27, 2022
Opening the discussion on the management of BPDCN, an expert panel consisting of two hematologist-oncologists and a pathologist, considers the causes, incidence and diagnostic approach to this rare disease.
FDA Approves Eflapegrastim for Chemotherapy-Induced Neutropenia
September 09, 2022
The FDA has approved eflapegrastim-xnst injection for adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs linked with clinically significant incidence of febrile neutropenia.
Recommendations for Diagnosing and Treating Rare Histiocytic Neoplasms
September 08, 2022
Ronald S. Go, MD, discusses what community oncologists should know regarding the guidelines on managing patients with histiocytic neoplasms.
FDA Approves a New Pegfilgrastim Biosimilar for Febrile Neutropenia
September 07, 2022
Pegfilgrastim-fpgk has been approved by the FDA for patients with febrile neutropenia following data which revealed it to have a high degree of similarity with its reference product.